Valneva (NASDAQ:VALN) Stock Price Down 4.9% - Here's Why

Key Points

• Valneva's stock price decreased by 4.9%, trading at $10.60, which is significantly lower than its previous close of $11.14, with an unusually low trading volume of 2,233 shares.
• Wall Street analysts have mixed ratings on Valneva, with a consensus rating of "Moderate Buy" and a price target averaging around $15.00, while ratings range from "buy" to a "sell (d-)" from Weiss Ratings.
• The company reported a loss of ($0.16) earnings per share for the last quarter, outperforming analyst expectations, and generated revenue of $54.84 million, exceeding estimates of $46.28 million.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) traded down 4.9% during mid-day trading on Friday . The stock traded as low as $10.64 and last traded at $10.60. 2,233 shares were traded during trading, a decline of 97% from the average session volume of 70,987 shares. The stock had previously closed at $11.14.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on VALN shares. Wall Street Zen upgraded Valneva to a "hold" rating in a report on Saturday, September 6th. Jefferies Financial Group set a $14.00 price objective on Valneva and gave the company a "buy" rating in a report on Monday, August 25th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Valneva in a research note on Monday, August 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Valneva in a research note on Wednesday. Finally, Guggenheim decreased their target price on shares of Valneva from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Monday, September 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Valneva presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Valneva Stock Performance

The stock has a market capitalization of $897.97 million, a P/E ratio of -10.66 and a beta of 1.86. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The stock's 50-day simple moving average is $9.80 and its 200 day simple moving average is $7.59.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. The business had revenue of $54.84 million during the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. Research analysts expect that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Large investors have recently bought and sold shares of the company. Marex Group plc bought a new position in shares of Valneva during the second quarter valued at $64,000. GAMMA Investing LLC bought a new stake in shares of Valneva in the 1st quarter valued at $94,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Valneva in the 2nd quarter valued at about $8,240,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.